Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission

AIDS

Volumn 14, Issue 11, 2000, Pages

  Jackson, J Brooks ^a   Becker Pergola, Graziella ^a   Guay, Laura A ^a   Musoke, Philippa ^b   Mracna, Martin ^a   Fowler, Mary Glenn ^c,d   Mofenson, Lynne M ^c   Mirochnick, Mark ^e   Mmiro, Francis ^b   Eshleman, Susan H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Africa; Clinical trials; HIV drug resistance; Resistance mutations; Reverse transcriptase inhibitors; Uganda; Vertical transmission

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UGANDA; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION; VIRUS TYPING;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; UGANDA;

EID: 0033816265     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00001     Document Type: Article

References (13)

1. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial
2. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team
3. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
4. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
5. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naive Ugandan adults
6. Dual transmission of subtype A and D HIV-1 viruses from a Ugandan woman to her infant
7. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
8. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076
9. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
10. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
11. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
12. CDC U.S. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States